These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 24252529)

  • 1. [Pharmacokinetic interactions].
    Arazo Garcés P; de los Santos Gil I
    Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():12-9. PubMed ID: 24252529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Mechanism of action and pharmacokinetics of rilpivirine].
    Portilla J; Estrada V
    Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():2-5. PubMed ID: 24252527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Data on rilpivirine in treatment-naïve patients. Lessons from ECHO, THRIVE and STaR].
    Domingo P; Ribera E
    Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():20-9. PubMed ID: 24252530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Resistance profile of rilpivirine].
    Imaz A; García F; di Yacovo S; Llibre JM
    Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():36-43. PubMed ID: 24252532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical perspective on drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor rilpivirine.
    Crauwels H; van Heeswijk RP; Stevens M; Buelens A; Vanveggel S; Boven K; Hoetelmans R
    AIDS Rev; 2013; 15(2):87-101. PubMed ID: 23681436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744.
    Ford SL; Gould E; Chen S; Margolis D; Spreen W; Crauwels H; Piscitelli S
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5472-7. PubMed ID: 23979733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rilpivirine: a second-generation nonnucleoside reverse transcriptase inhibitor.
    James C; Preininger L; Sweet M
    Am J Health Syst Pharm; 2012 May; 69(10):857-61. PubMed ID: 22555080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Introduction. Rilpivirine].
    Podzamczer D
    Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():1. PubMed ID: 24252526
    [No Abstract]   [Full Text] [Related]  

  • 9. Rilpivirine: a next-generation non-nucleoside analogue for the treatment of HIV infection.
    Fernández-Montero JV; Vispo E; Anta L; de Mendoza C; Soriano V
    Expert Opin Pharmacother; 2012 May; 13(7):1007-14. PubMed ID: 22519768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rilpivirine, a novel non-nucleoside reverse transcriptase inhibitor for the management of HIV-1 infection: a systematic review.
    Schafer JJ; Short WR
    Antivir Ther; 2012; 17(8):1495-502. PubMed ID: 22878339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens.
    Mills AM; Cohen C; Dejesus E; Brinson C; Williams S; Yale KL; Ramanathan S; Wang MH; White K; Chuck SK; Cheng AK
    HIV Clin Trials; 2013; 14(5):216-23. PubMed ID: 24144898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rilpivirine: drug profile of a second-generation non-nucleoside reverse transcriptase HIV-inhibitor.
    Ripamonti D; Bombana E; Rizzi M
    Expert Rev Anti Infect Ther; 2014 Jan; 12(1):13-29. PubMed ID: 24308712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Pharmacokinetics and Pharmacodynamics of Etravirine: An Updated Review.
    Havens JP; Podany AT; Scarsi KK; Fletcher CV
    Clin Pharmacokinet; 2020 Feb; 59(2):137-154. PubMed ID: 31679131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [RILPIVIRINE -- a novel HIV-1 non-nucleoside reverse transcriptase inhibitor].
    Snopková S; Havlíčková K; Polák P; Šlesinger P; Husa P
    Klin Mikrobiol Infekc Lek; 2013 Mar; 19(1):19-22. PubMed ID: 23945833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 96-Week resistance analyses of rilpivirine in treatment-naive, HIV-1-infected adults from the ECHO and THRIVE Phase III trials.
    Rimsky L; Van Eygen V; Hoogstoel A; Stevens M; Boven K; Picchio G; Vingerhoets J
    Antivir Ther; 2013; 18(8):967-77. PubMed ID: 23714781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies.
    Anta L; Llibre JM; Poveda E; Blanco JL; Alvarez M; Pérez-Elías MJ; Aguilera A; Caballero E; Soriano V; de Mendoza C;
    AIDS; 2013 Jan; 27(1):81-5. PubMed ID: 22842995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rilpivirine: a novel non-nucleoside reverse transcriptase inhibitor.
    Garvey L; Winston A
    Expert Opin Investig Drugs; 2009 Jul; 18(7):1035-41. PubMed ID: 19548857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Etravirine drug interactions].
    Pérez VE; Sánchez-Parra C; Serrano Villar S
    Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():27-31. PubMed ID: 20116625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE Studies.
    Nelson MR; Elion RA; Cohen CJ; Mills A; Hodder SL; Segal-Maurer S; Bloch M; Garner W; Guyer B; Williams S; Chuck S; Vanveggel S; Deckx H; Stevens M
    HIV Clin Trials; 2013; 14(3):81-91. PubMed ID: 23835510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy, pharmacokinetics, and safety of a nevirapine to rilpivirine switch in virologically suppressed HIV-1-infected patients.
    Rokx C; Blonk M; Verbon A; Burger D; Rijnders BJ
    J Acquir Immune Defic Syndr; 2015 Jan; 68(1):36-9. PubMed ID: 25247434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.